NCT03080974 Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
| NCT ID | NCT03080974 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Louisville |
| Condition | Pancreatic Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2017-08-14 |
| Primary Completion | 2028-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 10 participants in total. It began in 2017-08-14 with a primary completion date of 2028-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
Eligibility Criteria
Inclusion Criteria: * ≥ 18 years if age * Diagnosed with stage III pancreatic cancer * Tumor is measurable * Glomerular Filtration Rate \> 60 m/L/min/1.73 m(2) * Willing and able to comply with the protocol requirements * Able to comprehend and have signed the informed consent to participate Exclusion Criteria: * Participating in another clinical trial for the treatment of cancer at time of screening * Are pregnant or currently breast feeding * Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure * Have non-removable implants with metal parts within 1 cm of the target lesion * Had a myocardial infarction within 3 months prior to enrollment
Contact & Investigator
Robert Martin, MD, PhD
PRINCIPAL INVESTIGATOR
University of Louisville
Frequently Asked Questions
Who can join the NCT03080974 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03080974 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT03080974 currently recruiting?
Yes, NCT03080974 is actively recruiting participants. Contact the research team at robert.martin@louisville.edu for enrollment information.
Where is the NCT03080974 trial being conducted?
This trial is being conducted at Louisville, United States.
Who is sponsoring the NCT03080974 clinical trial?
NCT03080974 is sponsored by University of Louisville. The principal investigator is Robert Martin, MD, PhD at University of Louisville. The trial plans to enroll 10 participants.